Published in Semin Perinatol on January 12, 2016
Improving Outcomes in Neonatal Abstinence Syndrome | NCT01958476
Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA (2012) 5.10
The genetics of addictions: uncovering the genes. Nat Rev Genet (2005) 5.05
Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med (2010) 3.84
Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry (2000) 3.33
Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther (1994) 2.90
Neonatal drug withdrawal. Pediatrics (2012) 2.86
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA (2013) 2.34
Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012. MMWR Morb Mortal Wkly Rep (2014) 2.21
Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics (2006) 1.73
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction (2010) 1.71
ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol (2012) 1.71
The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag (2009) 1.70
Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. J Perinatol (2006) 1.61
Neonatal drug therapy: The first frontier of therapeutics for children. Clin Pharmacol Ther (2015) 1.60
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend (2010) 1.55
Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth (2004) 1.53
Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res (2004) 1.53
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med (2015) 1.48
Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr (2010) 1.46
Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr (1991) 1.39
Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann Neurol (2012) 1.39
Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend (2003) 1.36
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics (2009) 1.33
Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol (2008) 1.33
Methadone versus morphine for treatment of neonatal abstinence syndrome: a prospective randomized clinical trial. J Perinatol (2014) 1.28
A retrospective study of length of hospital stay in infants treated for neonatal abstinence syndrome with methadone versus oral morphine preparations. Adv Neonatal Care (2005) 1.28
Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr (2002) 1.26
Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction (2012) 1.25
Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend (2009) 1.25
Neonatal abstinence syndrome. Pediatrics (2014) 1.22
Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn (2006) 1.20
Prescription opioid epidemic and infant outcomes. Pediatrics (2015) 1.19
Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev (2010) 1.16
Management of neonatal abstinence syndrome: a national survey and review of practice. Arch Dis Child Fetal Neonatal Ed (2009) 1.15
Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol (2013) 1.15
Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol (2002) 1.14
Variation in treatment of neonatal abstinence syndrome in US children's hospitals, 2004-2011. J Perinatol (2014) 1.13
Substance use during pregnancy: risk factors and obstetric and perinatal outcomes in South Australia. Aust N Z J Obstet Gynaecol (2005) 1.11
A multicenter cohort study of treatments and hospital outcomes in neonatal abstinence syndrome. Pediatrics (2014) 1.11
Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict (2013) 1.10
Neonatal seizures: treatment and treatment variability in 31 United States pediatric hospitals. J Child Neurol (2009) 1.08
Volumetric cerebral characteristics of children exposed to opiates and other substances in utero. Neuroimage (2007) 1.06
Prenatal methadone exposure and neonatal neurobehavioral functioning. Pediatr Res (2009) 1.02
Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev (2013) 1.01
A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch Dis Child Fetal Neonatal Ed (2004) 1.00
The relationship between maternal opioid agonists and psychiatric medications on length of hospitalization for neonatal abstinence syndrome. J Addict Med (2011) 0.98
Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr (2008) 0.98
Morphine withdrawal-induced morphological changes in the nucleus accumbens. Eur J Neurosci (2005) 0.97
Neonatal abstinence syndrome. Curr Opin Pediatr (2012) 0.97
Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction (2012) 0.96
Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol (2015) 0.96
Sedatives for opiate withdrawal in newborn infants. Cochrane Database Syst Rev (2010) 0.96
Finnegan neonatal abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-addicted infants. Addiction (2010) 0.96
Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. Drug Alcohol Depend (2012) 0.95
The impact of intrauterine exposure versus postnatal environment in neurodevelopmental toxicity: long-term neurobehavioral studies in children at risk for developmental disorders. Toxicol Lett (2003) 0.92
Opioid prescription claims among women of reproductive age--United States, 2008-2012. MMWR Morb Mortal Wkly Rep (2015) 0.88
Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr (2014) 0.88
Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse (1989) 0.87
Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. J Clin Pharmacol (2010) 0.87
Neurodevelopmental and psychological assessment of adolescents born to drug-addicted parents: effects of SES and adoption. Child Abuse Negl (2010) 0.86
Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev (2014) 0.86
Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther (1978) 0.85
Infant and maternal characteristics in neonatal abstinence syndrome--selected hospitals in Florida, 2010-2011. MMWR Morb Mortal Wkly Rep (2015) 0.85
Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol (2002) 0.83
Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clin Pediatr (Phila) (1990) 0.83
Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend (2013) 0.82
The pharmacokinetics of methadone and its metabolites in neonates, infants, and children. Paediatr Anaesth (2014) 0.82
Opiate exposure and withdrawal dynamically regulate mRNA expression in the serotonergic dorsal raphe nucleus. Neuroscience (2013) 0.81
Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther (2014) 0.81
Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend (2015) 0.80
Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy (2015) 0.79
Role of noradrenergic hyperactivity in neonatal opiate abstinence. Drug Alcohol Depend (1996) 0.79
Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. Contemp Clin Trials (2014) 0.79
Oral morphine weaning for neonatal abstinence syndrome at home compared with in-hospital: an observational cohort study. Paediatr Drugs (2015) 0.78
Alternative matrices for cocaine, heroin, and methadone in utero drug exposure detection. Ther Drug Monit (2013) 0.77
The use of phenobarbital in treating abstinence in newborns exposed in utero to psychoactive agents. NIDA Res Monogr (1984) 0.76
Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp (2014) 0.75